Engineered immune cells take on advanced cancers in early trial
NCT ID NCT06237881
First seen Jan 09, 2026 · Last updated Apr 25, 2026 · Updated 17 times
Summary
This early-phase study tests whether a new cell therapy called KSQ-001EX is safe for people with advanced solid tumors, including melanoma, lung cancer, and head & neck cancers. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are genetically modified to boost their cancer-fighting ability. The study involves 15 participants and focuses on tracking side effects and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.